Tag: Zantrene

16 Mar

Race CEO Phil Lynch Talks with Proactive at the ASX Small and Mid-Cap Conference

Daniel Tillett Featured, Media Release, Video , , , ,

Read More
16 Mar

Race Oncology ASX Small and Mid Cap Conference Presentation

Daniel Tillett Featured, Media Release, Video , , ,

Read More
Proactive interview with Dr Daniel Tillett
11 Mar

CSO Dr Daniel Tillett talks to Proactive about recent kidney cancer results

Daniel Tillett Featured, Video , , , , ,

Read More
10 Mar

Compelling Preclinical Kidney Cancer Results for Zantrene

Daniel Tillett ASX Release, Featured, Media Release , , ,

Read More
25 Jan

New Independent Study Identifies Activity of Zantrene in Type 2 Diabetes

Daniel Tillett Featured, Media Release , , ,

25 January 2022 – Race Oncology Limited (“Race”) is pleased is pleased to share details of a recent independent scientific publication in the journal Cells, confirming Zantrene® (bisantrene dihydrochloride) is a highly effective inhibitor of the Fat Mass and Obesity…

Read More